MRNA Technical Analysis



As of date:12/12/2024
MRNA stock price:42.82
MRNA 50 DMA:48.97
MRNA 200 DMA:92.98
MRNA MACD (200-50):44.01
MRNA RSI:60.35
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)60.35
Extremely
Oversold

Also see:
MRNA Market Cap History
MRNA Shares Outstanding History
MRNA YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree MRNA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Inogen Breaks Below 200-Day Moving Average - Notable for INGN
35 minutes ago


MEOH Makes Notable Cross Below Critical Moving Average
1 hour, 21 minutes ago


Upbound Group Breaks Below 200-Day Moving Average - Notable for UPBD
1 hour, 23 minutes ago


Notable Two Hundred Day Moving Average Cross - VTC
1 hour, 25 minutes ago


Notable Two Hundred Day Moving Average Cross - ASGI
1 hour, 25 minutes ago


Notable Two Hundred Day Moving Average Cross - STN
1 hour, 27 minutes ago


LQD Crosses Below Key Moving Average Level
1 hour, 32 minutes ago


PFF Makes Notable Cross Below Critical Moving Average
1 hour, 33 minutes ago


NYF Crosses Below Key Moving Average Level
1 hour, 33 minutes ago


Notable Two Hundred Day Moving Average Cross - PMF
1 hour, 37 minutes ago


PALL Crowded With Sellers
1 hour, 38 minutes ago


MMU Makes Notable Cross Below Critical Moving Average
1 hour, 43 minutes ago


HCRB Breaks Below 200-Day Moving Average - Notable for HCRB
1 hour, 43 minutes ago


DFAX Crosses Below Key Moving Average Level
1 hour, 45 minutes ago


CGXU Makes Notable Cross Below Critical Moving Average
1 hour, 45 minutes ago


More Technical Analysis News

MRNA Technical AnalysisMRNA RSI
Moderna, Inc. is a biotechnology company. Co. is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development.

When researching a stock like Moderna, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from MRNA Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for MRNA stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
MRNA DMAMRNA MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Moderna (MRNA) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

PFE Technical Analysis
PODD Technical Analysis
REGN Technical Analysis
RMD Technical Analysis
RVTY Technical Analysis
SOLV Technical Analysis
STE Technical Analysis
SYK Technical Analysis
TECH Technical Analysis
TFX Technical Analysis
More Healthcare companies »

 

MRNA Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.